

Financial Tear Sheet

Corporate Profile

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone.

"Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio®; and Skin family with AlloBurn™ brand. AmnioFix, EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a unique bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Primary IR Contact

Michael J. Senken
Chief Financial Officer
MiMedx Group, Inc.

Phone: 770-651-9066

E-mail:

investorrelations@mimedx.com

Stock Performance

MDXG (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$12.37
Change (%)	▼ 0.13 (1.04%)
Volume	806,418
52 Week Low	\$7.64
Market Cap	\$1,373,501,379
Rolling EPS	0.31
PE Ratio	39.9
Shares Outstanding	111,034,873

Data as of Dec 18, 2017 1:24 p.m. ET

■ MIMEDX GROUP INC
as of 12/15/2017



EDGAR Online

Recent Headlines & Events

Dec 14, 2017 - 6:26 p.m.

[MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Sellers](#)

Dec 13, 2017 - 7:01 a.m.

[MiMedx Forecasts 2018 Revenue To Be In The Range Of \\$383 Million To \\$387 Million](#)

Dec 12, 2017 - 2:38 p.m.

[MiMedx Announces Release Of 2018 Guidance And Shareholder Conference Call](#)

SEC Filings

Filing Date	Form
Dec 13, 2017	8-K
Nov 30, 2017	8-K
Nov 02, 2017	4
Nov 02, 2017	4

There are currently no events scheduled.

Corporate Governance

[Parker "Pete" H. Petit](#)

Chairman and Chief Executive Officer

[William C. Taylor](#)

President and Chief Operating Officer

[Michael J. Senken](#)

Chief Financial Officer

[Alexandra Haden](#)

General Counsel and Secretary

[Christopher M. Cashman](#)

EVP and Chief Commercialization Officer

[Deborah L. Dean](#)

Executive Vice President

[Thornton A. Kuntz](#)

Senior Vice President of Administration

[Michael W. Carlton](#)

Senior Vice President of Global Sales

[Marlene M. DeSimone](#)

Senior Vice President of Corporate Strategic Development

[Dr. I. Mark Landy](#)

Senior Vice President Strategic Initiatives

[Gloria Matthews, DVM, PhD, DACVS](#)

Senior Vice President, Research and Development

[Rebecca J. C. Brown, Ph.D.](#)

Vice President of Product Development

[Frank Burrows](#)

Vice President of Clinical and Scientific Liaison

[Donald E. Fetterolf, M.D.,FACP](#)

Chief Medical Officer

[Thomas J. Koob, PhD](#)

Chief Scientific Officer

[David H. Mason, Jr., M.D.](#)

Vice President of Medical Affairs for Clinical Practice

[Randall Spencer](#)

Vice President of Clinical Innovation

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed